Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Research & Development: 2016-2024

Historic Research & Development for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $50.3 million.

  • Organogenesis Holdings' Research & Development rose 27.81% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year decrease of 9.35%. This contributed to the annual value of $50.3 million for FY2024, which is 13.27% up from last year.
  • As of FY2024, Organogenesis Holdings' Research & Development stood at $50.3 million, which was up 13.27% from $44.4 million recorded in FY2023.
  • Organogenesis Holdings' 5-year Research & Development high stood at $50.3 million for FY2024, and its period low was $20.1 million during FY2020.
  • In the last 3 years, Organogenesis Holdings' Research & Development had a median value of $44.4 million in 2023 and averaged $44.8 million.
  • Data for Organogenesis Holdings' Research & Development shows a peak YoY skyrocketed of 53.05% (in 2021) over the last 5 years.
  • Over the past 5 years, Organogenesis Holdings' Research & Development (Yearly) stood at $20.1 million in 2020, then surged by 53.05% to $30.7 million in 2021, then grew by 29.34% to $39.8 million in 2022, then grew by 11.61% to $44.4 million in 2023, then rose by 13.27% to $50.3 million in 2024.